Suchen
Celcuity Inc
CELCZur Watchlist hinzufügen
124.470USD
-0.210-0.17%
Handelsschluss 05/13, 16:00（ET）Kurse um 15 Minuten verzögert
6.02BMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Celcuity Inc Unternehmen
Celcuity Inc. is a clinical-stage biotechnology company, which develops targeted therapies for the treatment of multiple solid tumor indications. Its lead therapeutic candidate is gedatolisib, a potent, small-molecule reversible inhibitor that selectively targets all Class I isoforms of phosphatidylinositol-3-kinase (PI3K) and the two mechanistic targets of rapamycin (mTOR) sub-complexes, mTORC1 and mTORC2. Its development programs for gedatolisib focus on the treatment of patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-), or HR+/HER2-, advanced or metastatic breast cancer and patients with metastatic castration resistant prostate cancer. A Phase III clinical trial of VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast has commenced. Its CELsignia companion diagnostic platform is able to analyze live patient tumor cells.
Celcuity Inc Informationen
BörsenkürzelCELC
Name des UnternehmensCelcuity Inc
IPO-datumSep 20, 2017
CEOSullivan (Brian F)
Anzahl der mitarbeiter87
WertpapierartOrdinary Share
GeschäftsjahresendeSep 20
Addresse16305 36th Ave N Ste 100
StadtMINNEAPOLIS
BörseNASDAQ OMX - NASDAQ BASIC
LandUnited States of America
Postleitzahl55446-4285
Telefon17633920767
Websitehttps://www.celcuity.com/
BörsenkürzelCELC
IPO-datumSep 20, 2017
CEOSullivan (Brian F)
Führungskräfte von Celcuity Inc
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Brian F. Sullivan
Mr. Brian F. Sullivan
Chairman of the Board, Chief Executive Officer, Co-Founder
Chairman of the Board, Chief Executive Officer, Co-Founder
3.12M
--
Mr. Richard J. Nigon
Mr. Richard J. Nigon
Independent Director
Independent Director
79.03K
-12.65%
Ms. Vicky Hahne, CPA
Ms. Vicky Hahne, CPA
Chief Financial Officer
Chief Financial Officer
19.81K
+4.79%
Dr. Richard E. Buller, M.D., Ph.D.
Dr. Richard E. Buller, M.D., Ph.D.
Independent Director
Independent Director
7.79K
+1.01%
Dr. Polly A. Murphy, DVM, Ph.D.
Dr. Polly A. Murphy, DVM, Ph.D.
Independent Director
Independent Director
5.00K
--
Dr. Lance G. Laing, Ph.D.
Dr. Lance G. Laing, Ph.D.
Co-Founder, Chief Science Officer, Vice President, Secretary, Director
Co-Founder, Chief Science Officer, Vice President, Secretary, Director
--
--
Mr. David F. Dalvey
Mr. David F. Dalvey
Independent Director
Independent Director
--
--
Dr. Leo T. Furcht, M.D.
Dr. Leo T. Furcht, M.D.
Independent Director
Independent Director
--
--
Dr. Charlotte Moser, M.D., Ph.D.
Dr. Charlotte Moser, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
--
--
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Brian F. Sullivan
Mr. Brian F. Sullivan
Chairman of the Board, Chief Executive Officer, Co-Founder
Chairman of the Board, Chief Executive Officer, Co-Founder
3.12M
--
Mr. Richard J. Nigon
Mr. Richard J. Nigon
Independent Director
Independent Director
79.03K
-12.65%
Ms. Vicky Hahne, CPA
Ms. Vicky Hahne, CPA
Chief Financial Officer
Chief Financial Officer
19.81K
+4.79%
Dr. Richard E. Buller, M.D., Ph.D.
Dr. Richard E. Buller, M.D., Ph.D.
Independent Director
Independent Director
7.79K
+1.01%
Dr. Polly A. Murphy, DVM, Ph.D.
Dr. Polly A. Murphy, DVM, Ph.D.
Independent Director
Independent Director
5.00K
--
Dr. Lance G. Laing, Ph.D.
Dr. Lance G. Laing, Ph.D.
Co-Founder, Chief Science Officer, Vice President, Secretary, Director
Co-Founder, Chief Science Officer, Vice President, Secretary, Director
--
--
Umsatzaufteilung
Relevante Daten wurden vom Unternehmen noch nicht offengelegt.
Relevante Daten wurden vom Unternehmen noch nicht offengelegt.
Nach Geschäftsbereich
Nach Region
Relevante Daten wurden vom Unternehmen noch nicht offengelegt.
Aktionärsstatistik
Aktualisiert: Sun, May 10
Aktualisiert: Sun, May 10
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
Baker Bros. Advisors LP
16.38%
Perceptive Advisors LLC
6.54%
Sullivan (Brian F)
6.46%
Avoro Capital Advisors LLC
6.44%
New Enterprise Associates (NEA)
4.73%
Andere
59.46%
Aktionäre
Aktionäre
Anteil
Baker Bros. Advisors LP
16.38%
Perceptive Advisors LLC
6.54%
Sullivan (Brian F)
6.46%
Avoro Capital Advisors LLC
6.44%
New Enterprise Associates (NEA)
4.73%
Andere
59.46%
Aktionärstypen
Aktionäre
Anteil
Hedge Fund
33.92%
Investment Advisor
23.78%
Investment Advisor/Hedge Fund
19.70%
Individual Investor
9.48%
Private Equity
6.96%
Research Firm
6.38%
Venture Capital
5.38%
Pension Fund
1.13%
Corporation
0.72%
Institutionelle Beteiligung
Aktualisiert: Wed, Apr 1
Aktualisiert: Wed, Apr 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2026Q1
415
47.21M
97.67%
+1.59M
2025Q4
299
39.79M
87.00%
+296.61K
2025Q3
298
39.50M
98.78%
+3.79M
2025Q2
215
31.87M
95.31%
+797.76K
2025Q1
207
31.06M
92.46%
-3.93M
2024Q4
197
30.50M
91.70%
-18.57K
2024Q3
181
30.14M
86.73%
+764.96K
2024Q2
164
29.36M
68.66%
+7.16M
2024Q1
155
22.20M
60.61%
+3.55M
2023Q4
137
16.81M
74.10%
+667.49K
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
Baker Bros. Advisors LP
7.92M
16.38%
--
--
Mar 20, 2026
Perceptive Advisors LLC
3.16M
6.54%
+203.88K
+6.90%
Dec 31, 2025
Sullivan (Brian F)
3.12M
6.46%
+96.19K
+3.18%
Sep 30, 2025
Avoro Capital Advisors LLC
3.11M
6.44%
+3.11M
--
Dec 31, 2025
New Enterprise Associates (NEA)
2.29M
4.73%
-625.00K
-21.47%
Mar 06, 2026
BlackRock Institutional Trust Company, N.A.
2.24M
4.64%
+199.90K
+9.78%
Dec 31, 2025
Soleus Capital Management, L.P.
1.81M
3.74%
+629.40K
+53.39%
Dec 31, 2025
Deerfield Management Company, L.P.
1.71M
3.55%
+980.47K
+133.66%
Dec 31, 2025
State Street Investment Management (US)
1.64M
3.39%
+914.89K
+126.58%
Dec 31, 2025
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: Sat, Dec 6
Aktualisiert: Sat, Dec 6
Name
Anteil
iShares Genomics Immunology and Healthcare ETF
5.06%
Virtus LifeSci Biotech Clinical Trials ETF
4.16%
Tema Oncology ETF
3.44%
Invesco Dorsey Wright Healthcare Momentum ETF
3.35%
ALPS Medical Breakthroughs ETF
1.34%
Invesco Dorsey Wright SmallCap Momentum ETF
0.89%
iShares Micro-Cap ETF
0.44%
VictoryShares US Small Mid Cap Value Momentum ETF
0.26%
Vanguard US Momentum Factor ETF
0.16%
State Street SPDR S&P Biotech ETF
0.15%
Mehr Anzeigen
iShares Genomics Immunology and Healthcare ETF
Anteil5.06%
Virtus LifeSci Biotech Clinical Trials ETF
Anteil4.16%
Tema Oncology ETF
Anteil3.44%
Invesco Dorsey Wright Healthcare Momentum ETF
Anteil3.35%
ALPS Medical Breakthroughs ETF
Anteil1.34%
Invesco Dorsey Wright SmallCap Momentum ETF
Anteil0.89%
iShares Micro-Cap ETF
Anteil0.44%
VictoryShares US Small Mid Cap Value Momentum ETF
Anteil0.26%
Vanguard US Momentum Factor ETF
Anteil0.16%
State Street SPDR S&P Biotech ETF
Anteil0.15%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Ex-Dividendentag
Art
Verhältnis
Keine Daten
Datum
Ex-Dividendentag
Art
Verhältnis
Keine Daten
